IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study

INTRODUCTION: The phase III IMbrave150 study established atezolizumab + bevacizumab as standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis reports efficacy and safety results in patients with baseline Barcelona Clinic Liver Cancer (BCLC) stage B d...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudo, Masatoshi, Finn, Richard S., Galle, Peter R., Zhu, Andrew X., Ducreux, Michel, Cheng, Ann-Lii, Ikeda, Masafumi, Tsuchiya, Kaoru, Aoki, Ken-ichi, Jia, Jing, Lencioni, Riccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521324/
https://www.ncbi.nlm.nih.gov/pubmed/37767068
http://dx.doi.org/10.1159/000528272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521324/
https://www.ncbi.nlm.nih.gov/pubmed/37767068
http://dx.doi.org/10.1159/000528272

Ejemplares similares